Nasal delivered COVID vaccine to block transmission of SARS-CoV-2

Project Member(s): Johansen, M., Hansbro, P.

Funding or Partner Organisation: NSW Department of Health
NSW Department of Health

Start year: 2023

Summary: We propose an 18-month research and development plan to rapidly progress our innovative vaccine towards Phase I clinical studies. We will assess whether nasal vaccination induces sustained immunity and protection from infection in animal models, including when used as a booster following injected vaccination. In partnership with local company Ab Initio Pharma, we will develop and test a powdered inhalable vaccine formulation, packaged in a user-friendly clinical nasal delivery device. Advantageously, this formulation will promote vaccine equity as it will not require cold chain transport, and only minimal support from community health workers, as no injections or sharps disposal is required.

FOR Codes: Treatment of human diseases and conditions, Respiratory diseases

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.